Home    Back

 303. Usher syndrome
 [ 3 clinical trials,    3 drugs（DrugBank: 0 drug),    0 target gene / 0 target pathway ] 

Searched query = "Usher syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03780257March 6, 20194 November 2019Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GeneA First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneRetinitis Pigmentosa;Usher Syndrome Type 2;Deaf Blind;Retinal Disease;Eye Diseases;Eye Diseases, Hereditary;Eye Disorders Congenital;Vision DisordersDrug: QR-421a;Other: Sham-procedureProQR TherapeuticsRecruiting18 YearsN/AAll18Phase 1/Phase 2United States;Belgium;Canada;France
2NCT02065011September 12, 201314 October 2019A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1BAn Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1BUsher SyndromeDrug: UshStatSanofiNot recruiting18 YearsN/AAll18Phase 1/Phase 2United States;France
3NCT01530659January 201210 December 2018Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaPhotoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and DensityRetinitis Pigmentosa;Usher Syndrome Type 2;Usher Syndrome Type 3Drug: NT-501;Procedure: ShamNeurotech PharmaceuticalsUniversity of California, San Francisco;FDA Office of Orphan Products DevelopmentNot recruiting18 Years55 YearsAll30Phase 2United States